European Respiratory Journal

Article	Citations
Comparison of oronasal and nasal masks in home mechanical ventilation: an observational cohort and bench study	939
Genome-wide association study of preserved ratio impaired spirometry (PRISm)	679
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	557
ERJPodcast November 2023: Children and the ERS	348
Leukocyte telomere length: the dawn of a new era of personalised medicine in fibrotic interstitial lung diseases?	319
Clinical challenges in applying the new lung function test interpretive strategies: navigating pitfalls and possible solutions	231
Adult-onset idiopathic peripheral pulmonary artery stenosis	187
ERJPodcast August 2023: Simplifying pharmacotherapy for patients with COPD	186
Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension	160
Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies	154
“Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.” A. Jouet, C. Gaudin, N. Badalato,et al.Eur Respir J2021; 57: 2002338.	150
Transbronchial cryobiopsy: the right procedure for the right patient in the right place at the right time	141
Predicting steroid responsiveness using airway smooth muscle in COPD: a HISTORIC study	138
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment	133
Reply: Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?	132
Previous exacerbations in newly diagnosed COPD patients: do they matter?	124
Airway autoantibodies are determinants of asthma severity	115
Effectiveness and safety of tofacitinibversuscalcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multi-centre cohort study	114
Oxidation alters IL-33 function: new insights in the biology of different forms of IL-33 and their relevance for COPD	114
Sorting the wheat from the chaff: the innovative case of precision transpulmonary metabolomics	113
CXCL6 in idiopathic pulmonary fibrosis: a novel mediator in the complex epithelial–mesenchymal crosstalk	110
The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series	108
Endothelial to mesenchymal transition: a novel pathological feature of pulmonary fibrosis	107
The right ventricle tamed	105
Does autonomous macrophage-driven inflammation promote alveolar damage in COVID-19?	105

Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	104
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	101
Reply to: Is there a kindling effect in COPD exacerbations?	100
Obstructive sleep apnoea, nocturnal hypoxaemia, and cognitive decline in elderly patients	95
Restrictive spirometry pattern and abnormal cardiopulmonary response to exercise in transthyretin cardiac amyloidosis	90
A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody® molecule	84
A randomised controlled trial of intrapleural balloon intercostal chest drains to prevent drain displacement	84
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	83
Pulmonary arterial wedge pressure in healthy subjects: a meta-analysis	82
TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension	81
Ethnicity corrections in pulmonary function test reports: what to do?	80
“Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.” F. Torres,	80
Reply to: The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension	78
Arousal threshold and the effect of CPAP on neurocognitive function: a new step towards a precision medicine approach for treating obstructive sleep apnoea	77
Video-based direct observation physiotherapy in children with cystic fibrosis: a randomised controlled trial	76
ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma	75
Interpreting blood eosinophil counts in health and obstructive lung disease	75
The discovAIR project: a roadmap towards the Human Lung Cell Atlas	74
The 10-year temporal evolution of respiratory support and associated outcomes in extremely premature infants: betting on a favourable forecast for the next decade	74
Defining trajectory in severe asthma: can it be changed?	73
Nasal CPAP increases alveolar number in a rhesus monkey model of moderate prematurity	71
10 pack-years of smoking: not the magic number for COPD risk and prognosis	71
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	71
Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial	71
Early respiratory system reactance predicts respiratory outcomes in preterm infants: a retrospective, multicentre study	70
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	70
Pulmonary gas exchange in relation to exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction	69
Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea	69
Early-life airway microbiome and childhood asthma development	69
“International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.” Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek,et al. Eur Respir J2014; 43: 343–373.	69
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component	68
Inhaled soluble guanylate cyclase stimulator for the treatment of pulmonary arterial hypertension: struggling to breathe easy	67
Bronchodilators in bronchiectasis: there is light but it is still too dim	67
Continuous Positive Airway Pressure and Mandibular Advancement Splints: The CHOICE Multi-center Open-Label Randomized Clinical Trial	66
Lung allograft transbronchial cryobiopsy for critical ventilated patients: a randomised trial	66
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	66
Reply to: Early-life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?	66
Reference equations for evaluation of spirometry function tests in South Asia, and among South Asians living in other countries	64
Feasibility of unsedated lung MRI in young children with cystic fibrosis	62
Transcriptomics of interstitial lung disease: a systematic review and meta-analysis	62
Quantitative texture-based analysis of pulmonary parenchymal features on chest CT: comparison with densitometric indices and short-term effect of changes in smoking habit	61
A breath of the future: a novel human model for COPD and beyond	58
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry	58
Impact of the COVID-19 pandemic on influenza and respiratory syncytial virus antibody titres in the community: a prospective cohort study in Neustadt, Thuringia, Germany	56
Viewpoint on WHO implementation guidance on tuberculosis infection prevention and control	56
Addressing the effect of ancestry on lung volume	55
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	53
Impact of COVID-19 social distancing measures on lung transplant recipients: decline in overall respiratory virus infections is associated with stabilisation of lung function	53
Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	53
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study	53

U-BIOPRED/BIOAIR proteins: inflammation or infection?	52
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	52
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond	52
The lung that rules the heart	52
The GOLD 2023 proposed taxonomy: a new tool to determine COPD etiotypes	52
More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice	51
Casting a wider net for tuberculosis cases	51
Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD	51
Reply to: Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	51
Association between the use of statins and risk of interstitial lung disease/idiopathic pulmonary fibrosis: time-dependent analysis of population-based nationwide data	50
Reply: Confounding in Mendelian randomisation studies	50
The coexistence of asthma and COPD: some considerations about prevalence and lung function decline	50
Can we call all obstructive lung diseases COPD?	49
Shorter duration of antibiotic therapy for exacerbation of COPD	49
Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate us	48
From small to big, using microRNA profiling to investigate infant origins of childhood asthma	48
Improved prediction of asthma exacerbations by measuring distal airway inflammation	47
Advances in pleural diseases	47
“Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats.” R. Dumitrascu, C. Kulcke, M. Königshoff,et al.Eur Respir J2011; 37: 1104–1118.	46
Regular, low-dose, sustained-release morphine for persisting breathlessness in interstitial lung disease: a randomised, double-blind, placebo-controlled, crossover trial	46
Comparison of the treatment guidelines for sarcoidosis: common sense in the search for evidence	46
Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy	45
Missing airways, ventilation defects and conductive airway physiology in asthma	44
Accelerated epigenetic aging worsens survival and mediates environmental stressors in fibrotic interstitial lung disease	44
Telerehabilitation: a key player in reducing the travel emissions cost of respiratory healthcare?	44
The blood transcriptional response in patients developing intensive care unit-acquired pneumonia	44
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease, but why were acute exacerbations not considered?	44
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	43
Detection ofM. tuberculosisDNA in peripheral blood mononuclear cells of tuberculosis contacts does not associate with blood RNA signatures for incipient tuberculosis	43
Extended D-dimer cut-offs and machine learning for ruling out pulmonary embolism in individuals undergoing computed tomography pulmonary angiography	43
Reply: Guideline recommendations don't exist in a vacuum	43
CD94+natural killer cells potentiate pulmonary ischaemia–reperfusion injury	43
Host–microbial interactions differ with age of asthma onset	43
Overweight and dysanapsis in childhood asthma	42
ERS/ATS spirometry interpretation standards: a gap in grading severity of airflow obstruction	42
Safety of early rehabilitation after acute pulmonary embolism	42
Endotypic traits of supine position and supine-predominant obstructive sleep apnoea in Asian patients	42
Reply to: Sputum colour matters: haemoptysis in a bronchiectasis registry	42
ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (FENO50)	41
PET-CT-guidedversusCT-guided biopsy in suspected malignant pleural thickening: a randomised trial	41
Reply: The concept and application of the treatable traits approach in interstitial lung disease and other chronic respiratory diseases	41
Fibroblast growth factor 10 reverses cigarette smoke- and elastase-induced emphysema and pulmonary hypertension in mice	41
The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital	40
Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing	40
Pulmonary phase contrast CT imaging: a novel setup at the Italian synchrotron for the study of fresh lungs at human scale	40
Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment	39
Implications of the new ERS/ATS standards on the interpretation of lung function tests	39
Reconciling the past and considering the future of pulmonary function test interpretation	39
Respiratory effort and hypertension in obstructive sleep apnoea	39
Crucial role of fatty acid oxidation in asthmatic bronchial smooth muscle remodelling	39
Hiding in plain sight: the evolving definition of chronic breathlessness and new ICD-11 wording	38
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	38
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	38
Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism	38
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	38
Local targeting of TSLP: feat or defeat	38
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	38
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	38
Methionine supplementation: potential for improving alveolar macrophage function through reverse cholesterol transport?	38
Insights into the clinical outcomes of bronchiectasis	37
Chymase-1: a “MAST”-er switch in COPD?	37
COPD detection in lung cancer screening programmes: “hitting two birds with one stone”	36
Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond	36
Lung cancer in pulmonary fibrosis: no room for nihilism!	36
Pleuroparenchymal fibroelastosis: so many unmet needs	36
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD	35
Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19	35
The transcriptomic landscape of diffuse radiological bronchiectasis	35
Bronchiectasis in low- and middle-income countries: the importance of the wider view	35
The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence	35
Dynamic lung compliance in non-smokers with asthma and fixed, non-reversible airflow obstruction	35
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis	35
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma	35
Accelerated decline in lung function in adults with a history of remitted childhood asthma	34
Soluble VE-cadherin: not just a marker of endothelial permeability	34
An interferon-inducible signature of airway disease from blood gene expression profiling	34
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD	33
A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease	33
PD-L1highAT2 cells: a new player for alveoli regeneration	33
Heterogeneity of treatment response in bronchiectasis clinical trials	33

The accuracy of forced vital capacity for diagnosing restrictive allograft syndrome and mixed phenotype of chronic lung allograft dysfunction	33
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al	33
Gas exchange: the neglected piece in the PAH puzzle	33
It is time to optimise the management of latent tuberculosis infection in children	33
The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?	32
Occupational inhalant exposures and longitudinal lung function decline	32
Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk?	32
The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories	32
Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls	32
Physical activity, sedentary behaviour and incidence of obstructive sleep apnoea in three prospective US cohorts	31
Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission and role for pre-test probability scores and home treatment	31
Similarity network fusion for the integration of multi-omics and microbiomes in respiratory disease	31
Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study	31
Socioeconomic biases in asthma control and specialist referral of possible severe asthma	31
Antibiotics for asthma attacks: masking uncertainty	30
Effect of surgical mask on exercise capacity in COPD: a randomised crossover trial	30
Reply to: Room for methodological improvement in gait speed study for COPD patients	30
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	29
Risk factors for mortality in patients with COVID-19 needing extracorporeal respiratory support	29
Repeatability of impulse oscillometry in patients with severe asthma	29
“Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial.” D. Sto	29
The potential and challenges of radiomics in uncovering prognostic and molecular differences in interstitial lung disease associated with systemic sclerosis	29
Survival trends in patients with chronic thromboembolic pulmonary hypertension: An observational study	29
Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis	29
Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis	29
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization	29
Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy	28
Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension	28
Outcomes over the first two years of treatment with mepolizumab in severe asthma	28
Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children	28
Cytokines as prognostic biomarkers in pulmonary arterial hypertension	28
Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)	28
Higher throughput drug screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia	28
Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic	28
European Respiratory Society statement on airway clearance techniques in adults with bronchiectasis	28
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	28
Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort	28
Aspergillustracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study	28
Validating the Breathing Vigilance Questionnaire for use in dysfunctional breathing	27
The antimicrobial peptide S100A8/A9 produced by airway epithelium functions as a potent and direct regulator of macrophage phenotype and function	27
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	27
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	27
Air pollution, SARS-CoV-2 incidence and COVID-19 mortality in Rome: a longitudinal study	27
Dietary intake of vitamin A, lung function and incident asthma in childhood	27
Interstitial lung abnormalities are associated with decreased mean telomere length	27
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)	27
Dysfunctional breathing after COVID-19: recognition and ramifications	27
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	27
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rareCFTRvariants: a viewpoint	27
The impact of outpatientversusinpatient management on health-related quality of life outcomes for patients with malignant pleural effusion: the OPTIMUM randomised clinical trial	27
COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy	27
SARS-CoV-2 infections in people with primary ciliary dyskinesia: neither frequent, nor particularly severe	26
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	26
Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism	26
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	26
Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension	26
Rothia mucilaginosais an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease	26
Effect of highversuslow dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial	26
Biomarker signatures for progressive idiopathic pulmonary fibrosis	26
Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis	26
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease	26
Dyspnoea and respiratory muscle ultrasound to predict extubation failure	26
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era	26
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis	26
Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial	25
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors	25
Pirfenidone in post-COVID19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomized clinical trial	25
Analyses of 1236 genotyped primary ciliary dyskinesia individuals identify regional clusters of distinct DNA variants and significant genotype–phenotype correlations	25
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	25
Age, host response, and mortality in COVID-19	25
Cigarette smoke augments CSF3 expression in neutrophils to compromise alveolar–capillary barrier function during influenza infection	25
Advancing patient-centred care in measuring response to biologics in severe asthma	25
Emergence of bedaquiline resistance in a high tuberculosis burden country	25
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test	24
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	24
Interstitial lung disease increases susceptibility to and severity of COVID-19	24
Tuberculosis and COVID-19 co-infection: description of the global cohort	24
Is long COVID an autoimmune disease?	24
Recommendations for respiratory syncytial virus surveillance at the national level	24
Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry	24
Genome-wide association study of chronic sputum production implicates loci involved in mucus production and infection	23
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry	23
European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness	23
Prognostic factors for development of acute respiratory distress syndrome following traumatic injury: a systematic review and meta-analysis	23
Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials	23
Asthma and cardiovascular disease: embracing disease heterogeneity is required	23
Real-world effectiveness of airway clearance techniques in children with cystic fibrosis	23
Association between e-cigarette exposure and ventilation homogeneity in young adults: a cross-sectional study	23
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	23
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	23
Treatment algorithm for pulmonary arterial hypertension	23
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase	23
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	23
Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia	23
Asthma remission: what is it and how can it be achieved?	23